US Edition
News from Pharmaphorum
If you want to know if Pharmaphorum is credible or reliable, look no further. We rank Pharmaphorum as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaDo you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmaphorum News
Johnson & Johnson · United StatesDizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short appe…See the Story
With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short
71% Center coverage: 32 sources
Closed & Collaborative H1 2025: Mergers, acquisitions, collaborations, and partnerships in life sciences
100% Center coverage: 1 sources
In pursuit of a cure for cancer: An ASCO 2025 discussion with Dr Danny Nguyen
100% Center coverage: 1 sources
A Look Back to ASCO 2025: Industry Comments From iOnctura and Asgard Therapeutics
100% Center coverage: 1 sources
